BRAF and neoplasm: A recent study employed the tumor-informed assay RaDaRTM (NeoGenomics, Inc., Fort Myers, FL, USA) to analyze ctDNA in 276 plasma samples collected prospectively from 66 resected stage II to IV melanoma patients undergoing definitive local treatment and some of the (neo)adjuvant treatment with anti-PD-1 monotherapy or with anti-CLTA-4 or BRAF/MEKi [85].